XTRA:RDC
XTRA:RDCConsumer Retailing

Assessing Redcare Pharmacy (XTRA:RDC) Valuation After Strong 2025 Sales Update

Sales update puts Redcare Pharmacy in focus Redcare Pharmacy (XTRA:RDC) is back on investors’ radar after reporting fourth quarter 2025 group sales of €794 million, compared with €675 million a year earlier, alongside full year sales of €2.9b versus €2.4b in 2024. See our latest analysis for Redcare Pharmacy. Despite the strong sales update, Redcare Pharmacy’s share price has had a weak run, with a 90 day share price return of 24.46% decline and a 1 year total shareholder return of 45.89%...
XTRA:MBG
XTRA:MBGAuto

Is Mercedes-Benz Group (XTRA:MBG) Attractive After Recent Share Price Weakness?

If you are wondering whether Mercedes-Benz Group is attractively priced right now, this article walks through what the current share price really reflects. The stock closed at €58.82, with returns of a 2.6% decline over 7 days, a 1.7% decline over 30 days, a 5.0% decline year to date, a 16.0% return over 1 year, 13.2% over 3 years and 65.6% over 5 years. This gives you a mix of shorter term weakness and longer term gains to think about. Recent coverage around Mercedes-Benz Group has focused...
XTRA:BC8
XTRA:BC8IT

Will AI-Driven Managed Services Shift Bechtle's (XTRA:BC8) Revenue Mix Toward More Resilient Contracts?

Recent coverage indicates that Bechtle AG’s AI-related services are helping drive higher-margin projects and growing recurring managed-service bookings across its European customer base. This shift toward AI-enabled, service-based work highlights how Bechtle may be reshaping its revenue mix toward more resilient, contract-driven income streams. Next, we’ll examine how rising AI-driven, higher-margin managed-service demand could influence Bechtle’s existing investment narrative and risk...
XTRA:SZU
XTRA:SZUFood

Will Südzucker's (XTRA:SZU) Return to Quarterly Profit Amid Falling Sales Change Its Risk Narrative?

Südzucker AG has reported past third-quarter 2025 results showing sales of €2,156 million, down from €2,374 million a year earlier, while net income improved to €3 million from a net loss of €119 million and basic loss per share from continuing operations narrowed to €0.02 from €0.62. Over the first nine months, sales fell to €6,355 million from €7,466 million and the company moved from €23 million net income to a €59 million net loss, highlighting that the recent quarterly profit comes...
XTRA:FRE
XTRA:FREHealthcare

How Fresenius Kabi’s T Cell Automation Deal At Fresenius SE KGaA (XTRA:FRE) Has Changed Its Investment Story

Earlier this week, Fresenius Kabi and TQ Therapeutics announced a development agreement giving Fresenius Kabi exclusive rights to integrate TQ’s proprietary cell selection technology into its Cue Cell Processing System for automated, high‑purity T cell isolation in cell and gene therapy manufacturing. This collaboration could materially enhance Fresenius’s position in advanced therapies by pairing TQ’s affinity-based cell isolation with Fresenius Kabi’s automation capabilities, potentially...